Method for treating an ID2-related disorder
Described herein is a method of treating an ID2-related disorder comprising administering to a patient in need thereof an ID2 inhibitor or derivative thereof.
1 . A method of treating an Id2-related disorder comprising administering to a patient in need thereof a therapeutically effective amount of an Id2 inhibitor or derivative thereof.
2 . The method of claim 1 , wherein the Id2-related disorder is selected from the group consisting of PKD, diabetes, and cancer.
3 . The method of claim 1 , wherein the Id2-related disorder is PKD.
4 . The method of claim 3 , wherein the PKD is ADPKD or ARPKD.
5 . The method of claim 1 , wherein the Id2 inhibitor is thiazolidinedione.
6 . The method of claim 1 , wherein the thiazolidinedione is a glitazone.
7 . The method of claim 6 , wherein the glitazone has the general formula selected from the group consisting of:
wherein R1 is selected from the group consisting of an aryl group and a substituted aryl group.
8 . The method of claim 7 , wherein the R1 group is selected from the group consisting of:
9 . The method of claim 7 , wherein the glitazone is selected from the group consisting of: (a) rosiglitazone, (b) ciglitazone, (c) pioglitazone, (d) troglitazone, (e) englitazone and (f) a derivative of (a)-(e).
10 . The method of claim 1 , wherein Id2 activity is decreased compared to a control.
11 . The method of claim 10 , wherein the decreased Id2 activity is due a decrease in gene expression of Id2 in comparison to a control.
12 . The method of claim 9 , wherein the glitazone is rosaglitazone.
13 . The method of claim 12 , wherein rosaglitazone is administered at a therapeutically effective dosage range between 1 mg/kg/day to 100 mg/kg/day.
14 . The method of claim 12 , wherein rosaglitazone is administered at a therapeutically effective dosage range between 10 to 80 mg/kg/day.